Drug
Islatravir clinical trials
Also written MK-8591.
- studies test it
- 27
- open now
- 2
- in phase 3
- 10
- first study started
- 2015
Keep track of what changes. Save the islatravir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
27 studies that test it; most in 2020 (7)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 7 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 10
- Phase 3
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 0
Often tested with
Tested in the same studies.
Doravirine (11) · Ulonivirine (4) · Lamivudine (2) · Lenacapavir (1) · Bictegravir (1) · Emtricitabine (1) · Tenofovir alafenamide (1) · MK-8591A (1)
Studies
Open first, then newest update. How each study uses islatravir is read from its arms, and is right about nine times in ten.
Testing it · 27
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07266831Written as ISL
- DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kgNot yet recruitingPhase 2Merck Sharp & Dohme LLCNCT07862569Written as DOR/ISL
- DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05705349Written as DOR/ISL
- Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)CompletedPhase 3Merck Sharp & Dohme LLCNCT04233879Written as DOR/ISL
- Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)TerminatedPhase 3Merck Sharp & Dohme LLCNCT04652700Written as ISL
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)CompletedPhase 3Merck Sharp & Dohme LLCNCT04223791Written as DOR/ISL
- A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)CompletedPhase 1Merck Sharp & Dohme LLCNCT07086079Written as DOR/ISL
- Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVActive, not recruitingPhase 2Gilead SciencesNCT05052996Written as ISL
- Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)TerminatedPhase 3Merck Sharp & Dohme LLCNCT04644029Written as Islatravir
- Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]CompletedPhase 2Merck Sharp & Dohme LLCNCT04564547Written as Islatravir
- A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05766501Written as DOR/ISL
- A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05631093Written as DOR/ISL
- A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05630755Written as DOR/ISL
- A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06891066Written as ISL
- Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)CompletedPhase 2Merck Sharp & Dohme LLCNCT04003103Written as Islatravir
- Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)CompletedPhase 1Merck Sharp & Dohme LLCNCT04515641Written as Islatravir
- A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)CompletedPhase 1Merck Sharp & Dohme LLCNCT06811246Written as Islatravir (ISL)
- Islatravir and Methadone Pharmacokinetics (MK-8591-029)CompletedPhase 1Merck Sharp & Dohme LLCNCT04568603Written as Islatravir
- Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)CompletedPhase 3Merck Sharp & Dohme LLCNCT04233216Written as ISL
- A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)CompletedPhase 1Merck Sharp & Dohme LLCNCT06719570Written as Islatravir
See all 27 studies that test islatravir →
Given in every arm · 1 — islatravir is usual care beside what is tested
Codes
What other systems call islatravir · ClinicalTrials.gg INT005843
- MeSH (NLM) C558823islatravirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) QPQ082R25DISLATRAVIR ANHYDROUSConfirmed FDA, NLM, Wikidata
- Wikidata Q24977417islatravirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174896IslatravirOne source FDA
- DrugBank DB15653One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C558823 | islatravir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | QPQ082R25D | ISLATRAVIR ANHYDROUS | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q24977417 | islatravir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174896 | Islatravir | One source FDA |
| DrugBank | DB15653 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.